Myoblate™

Radiofrequency ablation system for treatment of uterine fibroids

Uterine fibroids, also known as myomas, are very common benign tumours, especially in women in their 40s and early 50s. Myoblate™ can treat uterine fibroids safely and effectively.

Myoblate™ offers a minimally invasive, uterus preserving treatment for symptomatic fibroids up to 8 cm diameter. It is recommended that up to 5 fibroids can be treated in a single procedure.

Myoblate™ works efficiently alongside standard ultrasound systems and depending on clinical needs or preferences different ultrasound guided approaches can be used:

• Transvaginal or Transcervical – for treatment of intramural or submucosal fibroids.
• Laparoscopic – for treatment of subserosal fibroids

 How does Myoblate™ work?
(Transvaginal approach)

Step 1

The physician uses the ultrasound system to confirm the size and location of the uterine fibroid(s).

Step 2

After detecting the fibroids, the Myoblate™ electrode is attached to the transvaginal ultrasound probe using a non-conductive guide and inserted through the vaginal canal.

Step 3

The electrode is safely placed into the uterine fibroid and radiofrequency energy is delivered to treat it. Multiple ablations can be performed within a fibroid but a 1cm safety zone around the edge of the fibroid should always be maintained.

Step 4

After confirming that all fibroids are treated, the electrode is removed. Patients are normally released within a few hours, and experience progressive symptom relief and continual improvement over time.

 Benefits of Myoblate™

• Minimally-invasive, focussed treatment
• Uterus preserving ^1,2
• Choice of approach
• Compatible with existing ultrasound set ups
• Fast & simple procedure
• Rapid recovery^1,2                  
• Possible outpatient procedure
• Immediate reduction in bleeding and pain
• Quicker symptom relief than traditional surgical procedures
• Low risk of complications^1,2
• Low recurrence rate³
• Repeated procedure is possible

 About Myoblate™

The Myoblate™ system combines the Mygen V-1000 generator and RFP-300 cooling pump with a choice of 2 hyperechoic, internally cooled electrodes.

The Myoblate™ fixed tip electrode has a 1.0cm active tip for repeated 1.0cm ablations. The variable tip electrode has a 0.5cm to 4cm active tip, controlled by a thumb lever, so the user can vary the size of the ablation zone between ablations. 

Mygen V-1000

Myoblate™ electrodes

Note: Patient grounding pads and pump tubing required for the procedure is supplied with the electrode.

References:

1. Hyun Hee Cho, MD, PhD, Mee Ran Kim, MD, PhD*, and Jang Heub Kim, MD, PhD. Outpatient Multimodality Management of Large Submucosal Myomas Using Transvaginal Radiofrequency Myolysis. Journalof Minimally Invasive Gynecology, Vol 21, No 6, November/December 2014
2. Chung-Hoon Kim, So-Ra Kim, Hyang-Ah Lee, Sung-Hoon Kim, Hee-Dong Chae, and Byung-Moon Kang. Transvaginal ultrasound-guided radiofrequency myolysis for uterine myomas. Human Reproduction,Vol.26, No.3 pp. 559–563, 2011
3. Young Lee, MD, PhD, Hyun Hee Cho, MD, PhD, Jin Hong Kim, MD, PhD, Jang Heub Kim, MD, PhD, Mee Ran Kim, MD, PhD, Young Ok Lew, MD, PhD, and SungJin Hwang, MD, PhD. Radiofrequency Thermal Ablation of Submucosal Leiomyoma: A Preliminary Report on Health, Symptom, and Quality of Life Outcomes. JOURNAL OF GYNECOLOGIC SURGERY. Volume 26, Number 4, 2010